ºÚÁÏÍø¹ÙÍø

Novo Nordisk (China) Pharmaceuticals Co., Ltd. operates a manufacturing facility in Tianjin, focusing primarily on diabetes treatments. This site is part of the company's broader efforts to enhance its presence in the Chinese pharmaceutical market, which has been a strategic focus since the 1990s when Novo Nordisk first entered China. Recently, Novo Nordisk announced plans to invest $556 million to expand its Tianjin plant. This expansion aims to bolster production capabilities for its weight loss drug, Wegovy, which has gained significant traction since its approval as a weight loss therapy following its initial approval for type 2 diabetes treatment